Red Cell Distribution Width/Albumin Ratio as a Predictive Tool for Mortality of Patients With Burn Injuries
Measurement of Red Cell Distribution Width/Albumin Ratio as a Predictive Tool for 30-day Mortality of Patients With Burn Injuries
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Descripción detallada
The aim of this study is to evaluate the prognostic utility of the red cell distribution width/albumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.
Patients presenting with acute thermal injuries will be screened based on inclusion/exclusion criteria.
After consent, patients' characteristics (age, sex, weight), clinical parameters (total burn surface area, Abbreviated Burn Severity Index), and comorbidities will be recorded.
Emergency Department (ED) management (Arrival and Initial Stabilization)
• Primary survey (ATLS principles): Immediate stabilization of Airway, Breathing, Circulation, Disability, Exposure (ABCDE).
- Urinary catheter insertion to monitor urine output for proper resuscitation.
- TBSA will be estimated using the Rule of Nines
- All patients will be treated during the first 24 hours after burn injury guided by the Parkland Formula.
In-Hospital Resuscitation (0-72 h)
• Hemodynamic monitoring: ECG, pulse oximetry, respiratory rate, temperature, non-invasive blood pressure, arterial line if unstable, and central venous pressure.
• Transition to Day 2 (24-48 h post-burn): Continue Lactated Ringer's and consider colloid therapy (5% albumin or plasma) after 24 h to maintain oncotic pressure and reduce crystalloid load.
• Fluid adjustments according to urine output, mean arterial pressure with target MAP (≥65 mmHg), lactate clearance, and base deficit.
Laboratory and calculation:
On admission to ED, an arterial blood gas (ABG) sample will be collected to calculate base deficit (BD) and lactate level.
Simultaneously, venous blood will be drawn for C-reactive protein (CRP) and serum albumin, CBC, serum urea, creatinine, AST, ALT, and electrolytes (Na+, K+, Mg+) estimation.
Red Cell Distribution Width/Albumin will be calculated as:
((RDW (Standard Deviation of Red Blood Cell Volume / Mean Corpuscular Volume) × 100%.) / albumin (g/L)) from admission labs.
Serial: Lactate/Base Deficit at 6 hr, 12 hr, 24 hr as a monitor for proper resuscitation Calculation of Severity Scores
• R-Baux score: Age (years) + %TBSA + (17 × inhalation injury [yes=1, no=0])
• Abbreviated Burn Severity Index (ABSI): The ABSI includes five parameters: sex, age category, %TBSA, presence of full-thickness burns, and inhalation injury. Each parameter is assigned weighted points, and the total ABSI score is associated with graded survival probabilities.
Both scores will be calculated on admission and compared with admission (RDW/albumin) ratio to assess relative and incremental predictive value for 30-day mortality.
Supportive care:
- Early enteral nutrition, proper multimodal analgesia (paracetamol 1gm/8hr, nalbuphine 0.1mg/kg if VAS score>4), IV proton pump inhibitor to guard against curling ulcer, prophylactic anticoagulation to guard against DVT.
Vasopressors (norepinephrine) only after adequate fluid resuscitation guided by UOP, lactate and BD if MAP below 65 mmHg.
3 - Post-Resuscitation and Definitive Management Protocol (After 72 h) Hemodynamic stabilization (post-resuscitation phase) Transition from resuscitation fluids to maintenance fluids. Avoid "fluid creep" (excess positive balance leading to pulmonary edema, abdominal compartment). → cautious use of diuretics to mobilize edema.
Maintain: MAP ≥65 mmHg, urine output ≥0.5 mL/kg/h. Ongoing ventilatory support if required; lung-protective strategy for ARDS. Weaning as early as possible.
Infection prevention and sepsis monitoring
• Daily wound assessment for signs of infection, weekly or targeted wound/blood cultures and antibiotics only if infection is suspected/proven (not prophylactic).
Wound care and surgical management
• Regular dressing, use of negative-pressure wound therapy when indicated.
- Early excision and grafting after 72 hr. Pain and sedation control
- Multimodal analgesia, pre-procedure analgesia for dressing/grafting and long-term psychological and pain management.
Rehabilitation and functional recovery • Early physiotherapy, occupational therapy for daily living skills and psychosocial support for patient and family.
Criteria for transfer to ward • Hemodynamically stable, off vasopressors.
• Stable oxygenation without advanced ventilatory support.
• Tolerating enteral feeding.
• Wounds coverage completed or adequately covered with new TBSA% below 20%.
- Patients will be followed for 30 days at Ain Shams University burn unit. Measured outcomes
Primary outcome:
To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30-day hospital mortality in burn patients.
Secondary outcomes:
To determine the correlation between Red Cell Distribution Width/Albumin with:
- ICU length of stay
- Hospital length of stay
- Requirements of inotropes or vasopressors
- Duration of mechanical ventilation
- To compare Red Cell Distribution Width/albumin ratio with R-Baux score as a predictor of mortality in burn patients.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Ahlam M abdelnaby. study principal investigator, MBBCH, MSc .
- Número de teléfono: +201120327604
- Correo electrónico: g19-29502090100101@med.asu.edu.eg
Copia de seguridad de contactos de estudio
- Nombre: Sara H Saleh, MD
- Número de teléfono: +201001584305
Ubicaciones de estudio
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egipto, 11111
- Reclutamiento
- Ain Shams University
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Patients presenting with acute thermal injuries will be screened based on inclusion/exclusion criteria.
After consent, Patients' characteristics (age, sex, weight), clinical parameters (Total burn surface area, Abbreviated burn severity index), and comorbidities will be recorded.
Descripción
Inclusion Criteria:
- Age > 18 years.
- Both sexes.
- Patients with burn injuries (%TBSA >20%).
- Availability of complete laboratory data (RDW, albumin) on admission.
- Admission to ICU within 24 hours of burn injury.
Exclusion Criteria:
- Age <18 years.
- Patients with chronic hematologic disease.
- Pre-existing liver disease.
- Nephrotic syndrome.
- patients on chemotherapy.
- Patients with incomplete or missing lab records.
- Pregnant females.
- Patient or guardian refusal.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
|---|
|
• Patients with burn injuries (%TBSA >20%)
each patient will be followed for 30 days for mortality prediction
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
mortality in burn patients
Periodo de tiempo: 30 days
|
To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30 days hospital mortality in burn patients.
|
30 days
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
ICU length of stay
Periodo de tiempo: 30 days
|
To determine the correlation between Red Cell Distribution Width/Albumin with o ICU length of stay
|
30 days
|
|
Requirements of inotropes or vasopressors
Periodo de tiempo: 30 days
|
To determine the correlation between Red Cell Distribution Width/Albumin with o Requirements of inotropes or vasopressors |
30 days
|
|
Duration of mechanical ventilation
Periodo de tiempo: 30 days
|
To determine the correlation between Red Cell Distribution Width/Albumin with o Duration of mechanical ventilation |
30 days
|
|
To compare RDW/albumin ratio with Revised Baux score as a predictor of mortality in burn patient.
Periodo de tiempo: 30 days
|
Revised Baux score = (percent body surface burned) + (patient's age) + 17 (if inhalational injury is present) A higher Revised Baux score generally indicates a higher risk of mortality, with scores over 140 unsurvivable .
|
30 days
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Silla de estudio: Adel M Fahmy Shenouda, MD, Department of Anesthesia, Intensive care and pain management, Faculty of Medicine, Ain Shams University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- FMASU MD361/2025
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Marco de tiempo para compartir IPD
Criterios de acceso compartido de IPD
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .